Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Hemant S. Murthy, MD, Kwang Woo Ahn, PhD, Noel Estrada-Merly, MS, Lohith Gowda, MD, Bhagirathbhai Dholaria, MBBS, Susan Bal, MDMBBS, Hassan B. Alkhateeb, MD, Deepa Jagadeesh, MDMPH, Betul Oran, MDMS, Ryotaro Nakamura, MD, Bart L. Scott, MD, Craig S. Sauter, MD, Francine M. Foss, MD, Mohamed A kharfan-Dabaja, MDMBA, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134793

Published: 2020

Journal Articles

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Sagar S. Patel, MD, Kwang Woo Ahn, PhD, Manoj Khanal, BS, MS, Caitrin Fretham, MPH, Celalettin Ustun, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Shin Mineishi, MD, Bipin N. Savani, MD, Mohamed Sorror, MD MSc, Edward A. Stadtmauer, MD FACP, Brent Logan, PhD, Marcelo C. Pasquini, MDMS, Saurabh Chhabra, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140503

Published: 2020

Journal Articles

Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT)

Trent Wang, DO,MPH, Michael Scordo, MD, Kwang Woo Ahn, PhD, Stella Chen, MS, Mohamed A. Kharfan-Dabaja, MDMBA, Alex F. Herrera, MD, Mehdi Hamadani, MD, Craig S. Sauter, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-137237

Published: 2020

Journal Articles

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Betul Oran, MDMS, Kwang Woo Ahn, PhD, Caitrin Fretham, Mithun Vinod Shah, MD PhD, Ryotaro Nakamura, MD, Bart L. Scott, MD, Ronald Sobecks, MD, Uday Popat, MD, Wael Saber, MD MS

Blood (2019) 134 (Supplement_1): 253.

https://doi.org/10.1182/blood-2019-121970

Published: 2019

Journal Articles

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Nilanjan Ghosh, MD PhD, Sairah Ahmed, MD, Carlos Litovich, MPH, Kwang Woo Ahn, PhD, Manoj Khanal, Mohamed A Kharfan-Dabaja, MDMBA, Anna Sureda, MD PhD, Timothy S. Fenske, MD, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 319.

https://doi.org/10.1182/blood-2019-121849

Published: 2019

Journal Articles

Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?

Deepa Jagadeesh, MDMPH, Navneet S. Majhail, MD MS, He Yizeng, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Timothy S. Fenske, MD, Anna Sureda, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 785.

https://doi.org/10.1182/blood-2019-121347

Published: 2019

Journal Articles

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Sairah Ahmed, MD, Nilanjan Ghosh, MD PhD, Manoj Khanal, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Timothy S. Fenske, MD, Mohamed A Kharfan-Dabaja, MDMBA, Anna Sureda, MD PhD, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 3318.

https://doi.org/10.1182/blood-2019-121848

Published: 2019

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Narendranath Epperla, MD, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Mohamed A Kharfan-Dabaja, MD, Sonali M. Smith, MD, Anna Sureda, MD, Timothy S. Fenske, MD, Mehdi Hamadani, MD

Blood (2018) 132 (Supplement 1): 969.

https://doi.org/10.1182/blood-2018-99-110469

Published: 2018

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Saurabh Chhabra, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Sandeep Jain, MBBS, MRCP, Robert K. Stuart, MD, Matt Kalaycio, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, III, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 600.

https://doi.org/10.1182/blood.V130.Suppl_1.600.600

Published: 2017

Journal Articles

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report

Haesook T Kim, PhD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Matthew Davids, MD, Virginia Volpe, MD, Edwin Alyea, MD, Uday Popat, MD, Ronald Sobecks, MD, Wael Saber, MD MS, Jennifer Brownn, MD PhD

Blood (2017) 130 (Supplement 1): 667.

https://doi.org/10.1182/blood.V130.Suppl_1.667.667

Published: 2017

Journal Articles

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Bei Hu, Xiao Lin, ^, Hans C. Lee, MD, Xuelin Huang, PhD, Rebecca Slack, MS, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Richard E Champlin, MD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Ying Lee, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 4582.

https://doi.org/10.1182/blood.V130.Suppl_1.4582.4582

Published: 2017

Journal Articles

Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children

Andrew C. Harris, MD, Jaap Jan Boelens, MDPhD, Kwang Woo Ahn, PhD, Mingwei Fei, MS, Allistair Abraham, MD, Andrew Artz, MD, Christopher C. Dvorak, MD, Haydar Frangoul, MD, Cesar O Freytes, MD, Robert Peter Gale, MD PhD, Sanghee Hong, MD, Hillard M. Lazarus, MD, Shin Mineishi, MD, Taiga Nishihori, MD, Tracey O'Brien, MD, Kirsten M. Williams, MD, Marcelo C. Pasquini, MD, John E Levine, MD MS

Blood (2016) 128 (22): 664.

https://doi.org/10.1182/blood.V128.22.664.664

Published: 2016

Journal Articles

Significant Differences in Stem Cell Transplant Utilization Rates (STUR) of Autologous Hematopoietic Cell Transplant (AHCT) in Multiple Myeloma (MM) Based on Ethnicity without Differences in Efficacy. a CIBMTR Report

Jeffrey R. Schriber, MD, Parmeswaran Hari, MD MRCP, MS, Kwang Woo Ahn, PhD, Mingwei Fei, MS, Amrita Krishnan, MD, Anita D'Souza, MBBS, MD

Blood (2016) 128 (22): 1190.

https://doi.org/10.1182/blood.V128.22.1190.1190

Published: 2016

Journal Articles

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)

Brian T. Hill, MD PhD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Matt Kalaycio, MD FACP, Richard T. Maziarz, MD, Jorge E. Cortes, MD, Edwin Alyea, MD, Uday R. Popat, MD, Ronald M. Sobecks, MD, Wael Saber, MD MS

Blood (2016) 128 (22): 2256.

https://doi.org/10.1182/blood.V128.22.2256.2256

Published: 2016

Journal Articles

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTR®) Study

Aaron T. Gerds, MD MS, Matt E. Kalaycio, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Edwin P. Alyea, MD, Uday R. Popat, MD, Ronald M. Sobecks, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 2003.

https://doi.org/10.1182/blood.V126.23.2003.2003

Published: 2015

Journal Articles

Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Provides Durable Progression-Free Survival (PFS) in a Subset of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous (auto-) HCT

Timothy S. Fenske, MD MS, Tara M. Graff, DO, Kwang Woo Ahn, PhD, Alyssa DiGilio, MS, Sonali M. Smith, MD, Anna Sureda, MD PhD, Mehdi Hamadani, MD

Blood (2015) 126 (23): 197.

https://doi.org/10.1182/blood.V126.23.197.197

Published: 2015

Journal Articles

Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies

Alberto Mussetti, MD, Abraham Sebastian Kanate, MD, Mohamed A Kharfan-Dabaja, MD, Kwang Woo Ahn, PhD, Alyssa DiGilio, MS, Stefan O Ciurea, MD, Philippe Armand, MD PhD, Rachel B. Salit, MD, Timothy S. Fenske, MD MS, Sonali M. Smith, MD, Anna Sureda, MD PhD, Javier Bolanos-Meade, MD, Mehdi Hamadani, MD

Blood (2015) 126 (23): 194.

https://doi.org/10.1182/blood.V126.23.194.194

Published: 2015

Journal Articles

A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Brian C Shaffer, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Uday R. Popat, MD, Matt Kalaycio, MD, Richard T. Maziarz, MD, Edwin Alyea, MD, Ron M Sobecks, MD, Steven Z. Pavletic, MD, Martin S Tallman, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 64.

https://doi.org/10.1182/blood.V126.23.64.64

Published: 2015

Journal Articles

Early CMV Reactivation Still Remains a Cause of Increased Transplant Related Mortality in the Current Era: A CIBMTR Analysis

Muthalagu Ramanathan, MD, Pierre Teira, MD MS, Minoo Battiwalla, MDMS, A. John Barrett, MD FRCP, FRCPath, Caroline A Lindemans, MD PhD, Jeffery Auletta, MD, Kwang Woo Ahn, PhD, Min Chen, PhD, Marcie L Riches, MD MS, Michael Boeckh, MD

Blood (2014) 124 (21): 47.

https://doi.org/10.1182/blood.V124.21.47.47

Published: 2014

NARROW

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT)

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children

Significant Differences in Stem Cell Transplant Utilization Rates (STUR) of Autologous Hematopoietic Cell Transplant (AHCT) in Multiple Myeloma (MM) Based on Ethnicity without Differences in Efficacy. a CIBMTR Report

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTR®) Study

Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Provides Durable Progression-Free Survival (PFS) in a Subset of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous (auto-) HCT

Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies

A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Early CMV Reactivation Still Remains a Cause of Increased Transplant Related Mortality in the Current Era: A CIBMTR Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only